Analyst Estimates: Here's What Brokers Think Of AK Medical Holdings Limited (HKG:1789) After Its Half-Year Report

It's been a sad week for AK Medical Holdings Limited (HKG:1789), who've watched their investment drop 14% to HK$5.11 in the week since the company reported its half-year result. AK Medical Holdings reported CN¥765m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of CN¥0.18 beat expectations, being 3.9% higher than what the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on AK Medical Holdings after the latest results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the five analysts covering AK Medical Holdings are now predicting revenues of CN¥1.65b in 2026. If met, this would reflect an okay 6.0% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 2.6% to CN¥0.36. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥1.66b and earnings per share (EPS) of CN¥0.35 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

See our latest analysis for AK Medical Holdings

The analysts reconfirmed their price target of HK$8.01, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic AK Medical Holdings analyst has a price target of HK$8.66 per share, while the most pessimistic values it at HK$7.60. This is a very narrow spread of estimates, implying either that AK Medical Holdings is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 12% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 27% annually. So it's pretty clear that AK Medical Holdings is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that AK Medical Holdings' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple AK Medical Holdings analysts - going out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.